HUMAW (Humacyte, Inc. Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by HUMAW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | John Philip Bamforth | Director | A | — | — |
| 2026-06-12 | Brady W Dougan | Director | A | — | — |
| 2026-06-12 | Susan Richards Windham-Bannister | Director | A | — | — |
| 2026-06-12 | Diane Seimetz | Director | A | — | — |
| 2026-06-12 | Charles Bruce Green | Director | A | — | — |
| 2026-06-12 | Laura E Niklason | President, CEO and Director | A | — | — |
| 2026-06-12 | Max N. Wallace | Director | A | — | — |
| 2026-06-12 | Michael T. Constantino | Director | A | — | — |
| 2026-06-12 | Keith Anthony Jones | Director | A | — | — |
| 2026-06-12 | Kathleen Sebelius | Director | A | — | — |
| 2026-06-12 | Emery N. Brown | Director | A | — | — |
| 2026-05-20 | Michael T. Constantino | Director | Buy | — | — |
| 2026-05-20 | Shamik J Parikh | Chief Medical Officer | Sell | — | — |
| 2026-05-20 | Dale A. Sander | CFO and Chief Corp. Dev. Off | Sell | — | — |
| 2026-05-20 | Kathleen Sebelius | Director | Buy | — | — |
| 2025-12-08 | FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ | — | — | — | — |
| 2025-11-17 | Brady W Dougan | Director | A | — | — |
| 2025-11-17 | Laura E Niklason | President, CEO and Director | A | — | — |
| 2025-11-17 | Shamik J Parikh | Chief Medical Officer | A | — | — |
| 2025-11-17 | Dale A. Sander | CFO and Chief Corp. Deve. Off. | A | — | — |
| 2025-08-20 | Laura E Niklason | President, CEO and Director | Sell | — | — |
| 2025-08-20 | Brady W Dougan | Director | Sell | — | — |
| 2025-06-16 | Keith Anthony Jones | Director | A | — | — |
| 2025-06-16 | Todd Pope | Director | A | — | — |
| 2025-06-16 | Susan Richards Windham-Bannister | Director | A | — | — |
| 2025-06-16 | Emery N. Brown | Director | A | — | — |
| 2025-06-16 | Max N. Wallace | Director | A | — | — |
| 2025-06-16 | Diane Seimetz | Director | A | — | — |
| 2025-06-16 | Kathleen Sebelius | Director | A | — | — |
| 2025-06-16 | Charles Bruce Green | Director | A | — | — |
| 2025-06-16 | Michael T. Constantino | Director | A | — | — |
| 2025-06-16 | Brady W Dougan | Director | A | — | — |
| 2025-06-16 | John Philip Bamforth | Director | A | — | — |
| 2025-06-16 | Laura E Niklason | President, CEO and Director | A | — | — |
| 2025-04-15 | William John Scheessele | Chief Commercial Officer | Buy | — | — |
| 2025-04-14 | Dale A. Sander | CFO and Chief Corp. Deve. Off. | Buy | — | — |
| 2025-04-14 | Shamik J Parikh | Chief Medical Officer | Buy | — | — |
| 2025-04-08 | Kathleen Sebelius | Director | Buy | — | — |
| 2025-04-08 | Charles Bruce Green | Director | Buy | — | — |
| 2025-04-08 | Michael T. Constantino | Director | Buy | — | — |
| 2025-01-23 | Brady W Dougan | Director | A | — | — |
| 2025-01-23 | Heather Ledbetter Prichard | Chief Operating Officer | A | — | — |
| 2025-01-23 | Dale A. Sander | CFO and Chief Corp. Deve. Off. | A | — | — |
| 2025-01-23 | Shamik J Parikh | Chief Medical Officer | A | — | — |
| 2025-01-23 | Laura E Niklason | President, CEO and Director | A | — | — |
| 2025-01-23 | William John Scheessele | Chief Commercial Officer | A | — | — |
| 2025-01-23 | Yang Cao | Chief Regulatory Officer | A | — | — |
| 2024-12-20 | Heather Ledbetter Prichard | Chief Operating Officer | A | — | — |
| 2024-12-20 | Laura E Niklason | President, CEO and Director | A | — | — |
| 2024-12-20 | Dale A. Sander | CFO and Chief Corp. Deve. Off. | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | — | 18,312,735 | — |
| — | 10%+ Owner | 8,793,583 | — |
| — | President, CEO and Director | 1,392,091 | — |
| — | CFO and Chief Corp. Dev. Off | 307,813 | — |
| — | Chief Medical Officer | 272,713 | — |
| — | Director | 243,851 | — |
| — | Director | 210,000 | — |
| — | Director | 148,025 | — |
| — | Director | 60,565 | — |
| — | Chief Regulatory Officer | 52,519 | — |
| — | Director | 43,950 | — |
| — | Chief Commercial Officer | 22,018 | — |
| — | Director | 8,400 | — |
| — | Chief Surgical Officer | 7,877 | — |
| — | Chief Operating Officer | 2,625 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HUMAW quote page; the site-wide leaderboard is on the insider transactions hub.